Middle East & Africa Clinical Oncology Next Generation Sequencing Market Size & Outlook
Middle East & Africa clinical oncology next generation sequencing market, 2018-2030 (US$M)
Related Markets
MEA clinical oncology next generation sequencing market highlights
- The MEA clinical oncology next generation sequencing market generated a revenue of USD 7.9 million in 2022.
- The market is expected to grow at a CAGR of 10.5% from 2023 to 2030.
- In terms of segment, targeted sequencing and resequencing was the largest revenue generating technology in 2022.
- Whole Genome Sequencing is the most lucrative technology segment registering the fastest growth during the forecast period.
- Country-wise, South Africa is expected to register the highest CAGR from 2023 to 2030.
MEA data book summary
| Market revenue in 2022 | USD 7.9 million |
| Market revenue in 2030 | USD 17.6 million |
| Growth rate | 10.5% (CAGR from 2022 to 2030) |
| Largest segment | Targeted sequencing and resequencing |
| Fastest growing segment | Whole Genome Sequencing |
| Historical data covered | 2018 - 2021 |
| Base year for estimation | 2022 |
| Forecast period covered | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Whole Genome Sequencing, Whole Exome Sequencing, Targeted Sequencing and Resequencing |
| Key market players worldwide | Illumina Inc, Thermo Fisher Scientific Inc, Roche, Agilent Technologies Inc, Myriad Genetics Inc, PerkinElmer, Roche Holding AG, Pacific Biosciences of California Inc, Oxford Nanopore Technologies PLC, Paradigm Healthcare, Eurofins Scientific SE, Qiagen NV |
Other key industry trends
- In terms of revenue, MEA region accounted for 2.1% of the global clinical oncology next generation sequencing market in 2022.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 233.9 million by 2030.
Key Regions: U.S. , UK , Japan , Brazil , South Africa
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Clinical Oncology Next Generation Sequencing Market Scope
Clinical Oncology Next Generation Sequencing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Middle East & Africa clinical oncology next generation sequencing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to clinical oncology next generation sequencing market will help companies and investors design strategic landscapes.
Targeted sequencing and resequencing was the largest segment with a revenue share of 72.15% in 2022. Horizon Databook has segmented the Middle East & Africa clinical oncology next generation sequencing market based on whole genome sequencing, whole exome sequencing, targeted sequencing and resequencing covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Middle East & Africa clinical oncology next generation sequencing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Middle East & Africa clinical oncology next generation sequencing market databook
-
Our clientele includes a mix of clinical oncology next generation sequencing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa clinical oncology next generation sequencing market, including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa clinical oncology next generation sequencing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
MEA clinical oncology next generation sequencing ngs market size, by country, 2018-2030 (US$M)
Middle East & Africa Clinical Oncology Next Generation Sequencing Market Share, 2022 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
